In summary, in HER2-overexpressing BC, crosstalk between HER2 and TGF-β results in increased cancer cell proliferation, survival and invasion, accelerated metastasis in animal models, resistance to chemotherapy and HER2-targeted therapy and perhaps up-regulation of BCSCs. The gene discussed is ERBB2; the disease is cancer.